Poison Pills and Takeover Defenses

An acquirer starts quietly buying up a target's stock on the open market, aiming to build a large enough stake to force a takeover without the target board's cooperation. Before that stake gets dangerous, the target's board can trigger a defense that was already sitting on the shelf, unused, waiting for exactly this moment: the poison pill.

How it works

A poison pill is adopted by the board, often with little public notice, and sits dormant until a triggering event — almost always a single shareholder or group crossing a specified ownership threshold, commonly 10-20%, without board approval. Once triggered, all shareholders except the triggering party receive rights to buy new shares (or the acquirer's shares, in a "flip-over" version) at a fraction of market value, sometimes half price or less. Because the acquirer is excluded from this right, its percentage ownership gets massively diluted by everyone else's new cheap shares — turning what looked like a growing, threatening stake into a much smaller one relative to the now-larger share count.

The pill doesn't have to actually be triggered to work; its mere existence deters a hostile bidder from crossing the threshold in the first place, because doing so would be self-defeating. This buys the board time and leverage — time to find a competing bidder, negotiate a higher price, or simply refuse to engage, and leverage because a hostile acquirer effectively needs the board's cooperation (or a suit and a favorable court ruling) to get the pill removed.

Worked example

A target has 100 million shares outstanding. An acquirer builds a 15 million share stake (15%) and crosses the pill's 15% trigger threshold. The pill lets every other shareholder buy new shares at half of the current $40 market price.

1. Shares before dilution: acquirer holds 15 million of 100 million shares, or 15%.
2. New shares issued to everyone else: the other 85 million shares' holders exercise rights to buy an equivalent value of stock at half price — roughly doubling their effective share count, adding about 85 million new shares to the float.
3. Acquirer's stake after dilution: the acquirer still holds 15 million shares, but total shares outstanding have grown to roughly 185 million, so its ownership falls to $15\text{m}/185\text{m} \approx 8.1\%$ — and the acquirer's cost of continuing to build toward control has risen sharply, since it must now buy proportionally more shares to regain any given percentage.

What this means in practice

Poison pills are almost never actually triggered in practice — their value is as a deterrent and a negotiating tool, forcing a would-be acquirer to negotiate with the board rather than go around it. Courts (particularly in Delaware) generally uphold pills as valid so long as the board can show a legitimate threat and a proportionate response, which is why most public companies keep a pill ready to adopt on short notice even without one already in place.